Basic characteristics of patients
| Variable . | No ATG (n = 46) . | Early ATG (n = 33) . | Late ATG (n = 48) . | P . |
|---|---|---|---|---|
| Sex | N/S | |||
| Male | 28 | 20 | 22 | |
| Female | 18 | 13 | 26 | |
| Diagnosis | ||||
| Malignancy | 21 | 13 | 16 | .001 |
| Immunodeficiency (SCID) | 24 (17) | 10 (2) | 12 (2) | |
| Bone marrow failure | 0 | 1 | 3 | |
| Metabolic disease | 1 | 8 | 17 | |
| Refractory autoimmunity | 0 | 1 | 0 | |
| Age | .006 | |||
| Median | 1.8 | 5.5 | 2.3 | |
| Range | 0.1-12.2 | 0.1-22.7 | 0.2-21.2 | |
| Stem cell transplantation | N/S | |||
| First | 42 | 32 | 45 | |
| Second | 4 | 1 | 2 | |
| Third | 0 | 0 | 1 | |
| Conditioning regimen | ||||
| Myeloablative conditioning | 29 | 31 | 45 | <.001 |
| BU/CY | 1 | 24 | ||
| BU 85-95/FLU 160/(Clo) | 2 | 27 (+2) | 8 | |
| Treo 42/FLU 150 | 10 | 0 | ||
| Treo 42/CY 120 | 1 | |||
| BEAM | 1 | |||
| Total-body irradiation–based (12 to 14.4 Gy) | 6 | 2 | 6 | |
| BU 90/CY/VP-16 (TDM) | 3 | |||
| BU 90/CY 120/Mel 140 | 8 | 1 | ||
| Oral BU 16/CY 120 | 3 | |||
| Reduced-intensity conditioning | 16 | 2 | 3 | |
| Treo 36/FLU 150 | 10 | |||
| Treo 36/CY 200 | 6 | |||
| BU 3/8; CY 1/5; FLU 3/8 | 1 | 1 | ||
| BU 3/8; FLU 3/8 | 1 | 1 | ||
| FLU/CY 1/5 | 1 | |||
| No conditioning | 1 | 0 | 0 | |
| rATG Genzyme 10 mg/kg | 0 | 30 | 43 | |
| rATG Genzyme 5 mg/kg | 0 | 2 | 3 | |
| rATG Genzyme 20 mg/kg (HLH) | 0 | 1 | 2 | |
| UCB cell doses | ||||
| Nucleated cells per kilogram × 107 | .055 | |||
| Median | 8.1 | 5.8 | 7.3 | |
| Range | 2.6-17.7 | 0.8-33.2 | 0.8-28.0 | |
| CD34+ cells per kilogram × 105 | <.001 | |||
| Median | 3.4 | 1.4 | 2.2 | |
| Range | 0.4-29.6 | 0.2-9.5 | 0.2-9.7 | |
| HLA match (of 6 alleles) | ||||
| 6/6 | 18 | 18 | 13 | N/S |
| 5/6 | 25 | 13 | 28 | |
| 4/6 | 3 | 2 | 7 | |
| Number of UCB infused | ||||
| Single cord blood unit | 42 | 30 | 47 | |
| Double cord blood unit | 4 | 3 | 1 |
| Variable . | No ATG (n = 46) . | Early ATG (n = 33) . | Late ATG (n = 48) . | P . |
|---|---|---|---|---|
| Sex | N/S | |||
| Male | 28 | 20 | 22 | |
| Female | 18 | 13 | 26 | |
| Diagnosis | ||||
| Malignancy | 21 | 13 | 16 | .001 |
| Immunodeficiency (SCID) | 24 (17) | 10 (2) | 12 (2) | |
| Bone marrow failure | 0 | 1 | 3 | |
| Metabolic disease | 1 | 8 | 17 | |
| Refractory autoimmunity | 0 | 1 | 0 | |
| Age | .006 | |||
| Median | 1.8 | 5.5 | 2.3 | |
| Range | 0.1-12.2 | 0.1-22.7 | 0.2-21.2 | |
| Stem cell transplantation | N/S | |||
| First | 42 | 32 | 45 | |
| Second | 4 | 1 | 2 | |
| Third | 0 | 0 | 1 | |
| Conditioning regimen | ||||
| Myeloablative conditioning | 29 | 31 | 45 | <.001 |
| BU/CY | 1 | 24 | ||
| BU 85-95/FLU 160/(Clo) | 2 | 27 (+2) | 8 | |
| Treo 42/FLU 150 | 10 | 0 | ||
| Treo 42/CY 120 | 1 | |||
| BEAM | 1 | |||
| Total-body irradiation–based (12 to 14.4 Gy) | 6 | 2 | 6 | |
| BU 90/CY/VP-16 (TDM) | 3 | |||
| BU 90/CY 120/Mel 140 | 8 | 1 | ||
| Oral BU 16/CY 120 | 3 | |||
| Reduced-intensity conditioning | 16 | 2 | 3 | |
| Treo 36/FLU 150 | 10 | |||
| Treo 36/CY 200 | 6 | |||
| BU 3/8; CY 1/5; FLU 3/8 | 1 | 1 | ||
| BU 3/8; FLU 3/8 | 1 | 1 | ||
| FLU/CY 1/5 | 1 | |||
| No conditioning | 1 | 0 | 0 | |
| rATG Genzyme 10 mg/kg | 0 | 30 | 43 | |
| rATG Genzyme 5 mg/kg | 0 | 2 | 3 | |
| rATG Genzyme 20 mg/kg (HLH) | 0 | 1 | 2 | |
| UCB cell doses | ||||
| Nucleated cells per kilogram × 107 | .055 | |||
| Median | 8.1 | 5.8 | 7.3 | |
| Range | 2.6-17.7 | 0.8-33.2 | 0.8-28.0 | |
| CD34+ cells per kilogram × 105 | <.001 | |||
| Median | 3.4 | 1.4 | 2.2 | |
| Range | 0.4-29.6 | 0.2-9.5 | 0.2-9.7 | |
| HLA match (of 6 alleles) | ||||
| 6/6 | 18 | 18 | 13 | N/S |
| 5/6 | 25 | 13 | 28 | |
| 4/6 | 3 | 2 | 7 | |
| Number of UCB infused | ||||
| Single cord blood unit | 42 | 30 | 47 | |
| Double cord blood unit | 4 | 3 | 1 |
Nonparametric tests were performed. P < .05 is considered significant.
BEAM, carmustine, etoposide, cytarabine, melphalan; BU, busulfan; CY, cyclophosphamide; CLO, clofarabine; FLU, fludarabine; HLH, hemophagocytic lymphohistiocytosis; Mel, melphalan; N/S, nonsignificant; rATG, rabbit ATG; SCID, severe combined immunodeficiency; TDM, therapeutic drug monitoring; Treo, treosulfan; VP-16, etoposide.